• Marvel Biosciences signed a letter of intent with Novatech to run a Phase 1 clinical program for autism candidate MB-204.
• Trial planned in Australia, targeting first-in-human safety, tolerability, and pharmacokinetics; single ascending dose study expected to start in Q4 2026.
• Novatech to provide full-service CRO support, including trial management, site selection, regulatory submissions, biostatistics, and data management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marvel Biosciences Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060645PRIMZONEFULLFEED9839942) on October 06, 2026, and is solely responsible for the information contained therein.